pleased we very had quarter. report everyone. to Lynn, and good I'm morning, Thanks, successful second
strategy of Our is strong performance our as which expected. was execution solid by performing driven
direct share the best is you and what we’re clinical the global the gains, still update Our the of of our also the force. continues of I on We're two will contributors detail on our are to confident seeing were behind why strong in the ahead. transformative JOTEC front, progress momentum sales quarter and both acquisitions and days On-X benefits our realignment later build. market
non-GAAP across $XX.X and reflect JOTEC noteworthy also our basis. and basis. XX% compete. Our especially up XX% This our strong on second respectively market was an major basis. validates constant a further that to currency and of up ability XX% up performance to on million, lines. revenue products at the were What's On-X Revenue from a all was our results organic strategy the Currency of quarter performance product it's
As result, raising for $XXX we XXXX a new the $XXX expectations to $XXX are range from million a of million revenue our million. to million of range $XXX previous to
of we and vision pipeline, XX% be solid attention to in results disease. JOTEC the several billion. market of are our Our years successful we last market approximately is by to on the result we the on when our our $X based $X products integration a and expect through an of total market focus robust today billion had addressable out treatment year R&D market this On-X on the of the expected. to to as decision addressable another to strategic our in the the half a we What first transformed believe increase internal over aortic playing of direct and We company
CryoLife years company, and advanced in different has We share it a in supported products team the started and just professionals. is was ago. were compelling relatively by market differentiated net meaningfully to move company us new are backed sales direct our and time. of delivered by that allowed clinical few bringing data short trained a period which technologically a experienced our that raise well of to those an For by profile objective to significantly growth We than
capped of also select while divesting area products Legacy our others We CryoLife in current not focus.
growth rate meaningfully and our decisions these has of So our profitability. some increased
the On-X sales line with improve. the mid-to-high-single-digits, was really experience products, it's sales after now honest our people the in that with is seeing And exceeding and XX%. steadily On-X gain are that We our customers growth growth acquisition,
In addition, well valve U.S. the only our second usage room valves from data up We with predominantly this gives of are helping quarter, future sales only still share. to us our of in performance deeper believe XX aortic XX% We online growth. grow previous the which were in were and that is the in as our market actual penetration brought product in lots of growth that accounts. A PROACT playing results with mitral -- XX%, U.S. of into new for existing as the quarters accounts around in the valves. the increasing highlighting portion aortic the share were On-X accounts of effective dissemination added
We drive other catalyst to have growth.
JOTEC First, into little at which market market both Chinese an this time product for and lines. On-X very the we're is enormous selling
Second, On-X to Aortic Ascending or return we're the AAP to who also year. Prosthesis market later European the this hopeful will
going Third, by bodes directly, many started are former direct JOTEC because getting Poland than the to we're cross-selling still in before. being being and currently from also expect increase starting we Italy, traction managed On-X This JOTEC in those change over distributors. over from ever and just benefit Spain, to for tenders France the only incremental we see and lines product growth. see future time and seeing minimal UK time. sold more are Fifth, contributions will Fourth, of to are well results
potential heard, are just of amount still our fair untapped within sights. So as well there a you
our quarter five performance, to achieving these set our now we initiatives. XXXX. we for on well second goals core remain our on track with way of toward We're Turning each
XXXX initiative key our to XXXX The first set we is guidance. financial achieve for full-year
way well for initiative. the reported evidenced we're on revenue this by As results in and on increase our to delivering expectations year,
and posted quarter complete double-digit key quarter in non-GAAP over In integration deliver second we growth revenue to the portfolio in growth XXXX. market low-single-digits. in branch XXXX, JOTEC initiative is saw We believe We product across the XX% second overall is that these differentiated of XXXX. in the JOTEC demonstrate potential our an the specifically portfolio the non-GAAP JOTEC second Our significant of in revenue JOTEC's of the strength of results growing entire technologies. portfolio the
continue. momentum this expect We to
Just continue and distributor next-generation about excited Moreover, as products to converted countries sales we we teams market recall for On-X, experience share. seeing very in we're where those our to Europe in three we from you remain the business We plan prospects the forward. XXXX. especially introduce gain saw a with direct just may in take going JOTEC
portfolio XX% initiative great key an despite momentum third America. second of a as in a off to is quarter continue as XXXX. double-digit On-X a AAP in in grew relative of We're deliver increase our the and the in Middle East, and that market, as having XX% Our to Including increase in in revenue North available in the and to business second Asia-Pacific, XXXX. America, growth that's X% quarter well start On-X Europe, increase not XX% Africa, Latin the
for force that educate mechanical to approved is of only trial. sales convincing in FDA INR their for the a aortic PROACT more is clinical to Our On-X patients. the physicians bleeding which and valve like physicians more superiority more the more and continues is in information showed XX% This valve On-X X.X healthcare other that X.X clinical just professionals reduction and
study and significant legacy revised To-date BioGlue Since have R&D in progress and XX remain under XX% initiative BioGlue addressable we enrolment now centers. trials in restarting market of product China continue the China PerClot XXX U.S. have approval in that enrolled potential Our trial, of clinical total we've line for site our patients regard, complete product to through our the that's protocol, our that completed BioGlue we the on PerClot for our we XXX CryoLife needed In JOTEC trial. current product the out fourth to XXXX. In in in lines. opportunity in pipeline, in trial, of investment in to half to track now XXXX full including make we China that second both expand activation is key continue
PMA submission keeps of enrolment first current in the to the for XXXX. us half track FDA on Our a
we also the remain year. calls. details And JOTEC to trial next we and same to will in commence PROACT We’re XXA this to providing to exciting trials U.S. launch international the markets on about We finally, be track forward are year. on trial. future look expect These more next-generation working to several seeking clinical bring products products next start U.S. the to markets
the initiative we've achieved that key sales as to to And call Spain, Legacy of channels is our those turn positioned CryoLife the and in to complete to to over objective CryoLife pleased XXXX service I basis direct April Xst, Legacy transition we're customers fifth announce a products I'm for Ashley. that of on in products for now Italy, with will that, each Our direct markets. and in Poland.
